on a mobile?
vTap
    Loading...
 
suggest
 
Video
Europe's biggest drugmaker announces an "unprecedented" share buyback programme. 7/2007 Reuters
a year ago
Excite - Entertainment
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
GlaxoSmithKline
Go to Feed to see what's new!
share
keep
 
 
...GlaxoSmithKline Plc, talks with Bloomberg's Nina de Roy and Rishaad Salamat from Middlesex, England, about the safety of diabetes drug Avandia, the outlook for new products and second-quarter ...
a year ago
Bloomberg - Financial News
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
GlaxoSmithKline
Pharmaceutical company
Chief executive officer
Go to Feed to see what's new!
share
keep
 
 
Inside the numbers, with CNBC's Mike Huckman
2m 1s |
a year ago
CNBC Video Gallery - CNBC.com
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
CNBC
GlaxoSmithKline
Go to Feed to see what's new!
share
keep
 
 
...GlaxoSmithKline and Pozen. The companies must respond to the FDA about results from a preclinical study. ''Shrek The Third'' and DVD sales help lift Viacom to stronger second quarter profit. Diane ...
1m 20s |
a year ago
Reuters
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
Food and Drug Administration
GlaxoSmithKline
Viacom
Pharmaceutical company
Migraine
Go to Feed to see what's new!
share
keep
 
 
Insight on the pharma companys Avandia hearing, with CNBCs Mike Huckman
a year ago
MSN Video
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
GlaxoSmithKline
Go to Feed to see what's new!
share
keep
 
 
More Videos
 
Keep this video in the "Saved" list
Go to Feed to see what's new!
share
keep
 
 
 
 
GlaxoSmithKline says sales of its diabetes drug, Avandia, are sliding.But Europe's biggest drugmaker has softened the blow to investors. It's announced plans to double a share buyback to 12 billion pounds, or 25-billion U-S dollars. Chief Executive Jean-Pierre Garnier says a buyback programme of that scale is unprecedented in the drug industry. But Reuters editor Mike Dolan says some of that anxiety appears to have eased today;Report: Mike Dola.
1m 59s |
a year ago
AOL
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
Rosiglitazone
GlaxoSmithKline
A share
Go to Feed to see what's new!
share
keep
 
 

Corporate Home Corporate Home News FAQ About Contact Forums Send Feedback
Privacy Policy and Terms of Use